Ken Griffin Design Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,300 shares of DSGN stock, worth $15,226. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,300

Previous 1,100 109.09%

Holding current value

$15,226

Previous $3,000 300.0%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.19 - $5.88 $864,234 - $1.59 Million	270,920 Added 88.93%	575,550 $3.1 Million
Q2 2024 Aug 14, 2024	SELL	$3.23 - $4.77 $1.84 Million - $2.72 Million	-570,147 Reduced 65.18%	304,630 $1.02 Million
Q1 2024 May 15, 2024	SELL	$2.27 - $4.03 $2.17 Million - $3.86 Million	-957,477 Reduced 52.26%	874,777 $3.53 Million
Q4 2023 Feb 14, 2024	SELL	$1.99 - $2.76 $1.73 Million - $2.4 Million	-868,299 Reduced 32.15%	1,832,254 $4.86 Million
Q3 2023 Nov 14, 2023	SELL	$2.05 - $8.14 $318,883 - $1.27 Million	-155,553 Reduced 5.45%	2,700,553 $6.37 Million
Q2 2023 Aug 14, 2023	SELL	$4.99 - $7.64 $45,214 - $69,226	-9,061 Reduced 0.32%	2,856,106 $18 Million
Q1 2023 May 15, 2023	BUY	$5.5 - $9.77 $1.99 Million - $3.54 Million	362,606 Added 14.49%	2,865,167 $16.5 Million
Q4 2022 Feb 14, 2023	BUY	$7.86 - $17.2 $635,315 - $1.39 Million	80,829 Added 3.34%	2,502,561 $25.7 Million
Q3 2022 Nov 14, 2022	SELL	$14.09 - $25.57 $1.75 Million - $3.17 Million	-123,926 Reduced 4.87%	2,421,732 $40.5 Million

Others Institutions Holding DSGN

# of Institutions

102

Shares Held

31M

Call Options Held

2.3K

Put Options Held

16.5K

View Full List

About Design Therapeutics, Inc.

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $369M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

More about DSGN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account